Tumor samples from 4,046 patients with invasive breast carcinoma were assessed for expression of T1GFR family members HER1, HER2, HER3 and HER4. In 10% of these tumors, HER3 overexpression was ...

HER2 amplification further drives oncogenesis by activating the MAPK and PI3K/Akt pathways, with HER3 and HER4 modulating these signals. The PI3K/Akt/mTOR pathway controls cell growth and ...

Part of the four-member HER family of proteins, HER3 is known to work with HER2 to play a role in treatment resistance.

EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody ... AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab ...

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate ... and this finding is in line with that hypothesis. Already-marketed HER2-targeting ADC Enhertu (trastuzumab ...